Finep / MCTIC provides R$ 600 million in credit to face COVID-19

Finep, a public company of the Ministry of Science, Technology, Innovations and Communications (MCTIC), has just approved credit lines, in the total amount of R$ 600 million, to face COVID-19.

This is yet another joint action between MCTIC and Finep that demonstrates the union of forces and different environments of S, T & I for the country to overcome the Coronavirus pandemic.

Finep / MCTIC has stipulated three specific lines, with special conditions, which will guarantee the development of technologies by companies.

The format is continuous flow, based on the rules that involve the company's repayable financing.

Check the details of the following lines:

Credit for Industrial Conversion

Support the transformation of factories to produce items necessary to fight the disease, using the accumulated knowledge of engineering, industrial production capacity and idle assets of companies (“war effort”).

Type: Direct Operation
Target Audience: Companies of all sizes
Rate: TJLP + 0.5% aa
Deadline
 – Total Grace Period: up to 24 months
 – Total Term: up to 72 months
Finep participation: 100%
Amount Available: R$ 150 million
Shelf life: 12/20 or interrupt at the discretion of Finep

Scaling for medical devices

Finance initiatives that seek to develop, optimize and scale health care devices used in ICUs as a way to increase the national supply of these products. These will be innovations at the level of the company itself and, in some cases, at the national level. 

Type: Direct Operation
Target Audience: Companies of all sizes
Rate: TJLP + 0.5% aa
Deadline
 – Total Grace Period: up to 48 months
 – Total Term: up to 144 months
Finep participation: 100%
Amount Available: R$ 150 million
Shelf life: 12/20 or interrupt at the discretion of Finep

Finep / MCTIC Innovative Health Acquisition

Finance the acquisition of essential devices for health institutions in the fight against COVID-19 by promoting the innovative capacity of the Industrial Health Complex, notably stimulating the demand for products developed by innovative SMEs.

Type: Indirect Operation
Target Audience: Companies of all sizes, especially private hospitals and Santas Casas
Rate: TJLP + 4,0% aa
Deadline
 – Total Grace Period: up to 24 months
 – Total term: up to 120 months
Finep participation: 100%
Amount Available: R$ 300 million
Shelf life: Undetermined